Title of article :
Does Garlic Supplementation Control Blood Pressure in Patients with Severe
Coronary Artery Disease? A Clinical Trial Study
Author/Authors :
Mahdaviroshan، Marjan نويسنده Students’ Research Committee, National Nutrition and Food Technology Research Institute Faculty of Nutrition Sciences and Food Technology , , Nasrollahzadeh، Javad نويسنده Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences. Tehran. Iran , , Mohammad Zadeh، Ali نويسنده Department of Radiology, Shaheed Rajaei Cardiovascular, Medical and Research Center, Tehran, Iran , , Zahedmehr، Ali نويسنده ,
Issue Information :
ماهنامه با شماره پیاپی 0 سال 2016
Abstract :
Hypertension is one of the major risk factors for cardiovascular
morbidities, including coronary artery disease (CAD). With interest on
the important role of hypertension in the progression of CAD, this study
was designed to estimate the effect of garlic powder tablets on the
blood pressure (BP) in patients with severe CAD. A randomized,
placebo-controlled, clinical trial was conducted on 56 CAD patients,
aged 25 - 75 years old. The patients were randomly divided into two
groups: Galois groups (n = 27), receiving garlic powder tablet (400 mg
garlic) twice daily and the placebo groups (n = 29), receiving placebo
for 3 months. The BP was assessed at baseline and at the end of the
study. During the 3 months study, in the placebo group, systolic BP
(SBP) increased with 6.3 mmHg and diastolic BP (DBP) increased with 4.6
mmHg, changes which were significant. After the 3 months, the effect of
garlic on SBP, after adjusting for baseline value, was significant, and
this effect was more significant in hypertensive patients. Plasma lipids
and lipoproteins did not change significantly in either the garlic or
placebo groups, during the study. Tolerability, compliance and
acceptability were high in all patients. These results demonstrate that
treatment with garlic-based drugs can be an effective treatment for
controlling BP in CAD patients and has no interaction with other drugs
that CAD patients take. Therefore, it may be considered as a safe
adjunct treatment for this group of patients.
Journal title :
Iranian Red Crescent Medical Journal
Journal title :
Iranian Red Crescent Medical Journal